AC Immune SA P / E
Was ist das P / E von AC Immune SA?
P / E von AC Immune SA ist 4.19
Was ist die Definition von P / E?
Das Terminkurs-Gewinn-Verhältnis ist das Verhältnis des Aktienkurses eines Unternehmens zum geschätzten Gewinn des Unternehmens je Aktie für die nächsten zwölf Monate.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P / E von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu AC Immune SA
Was macht AC Immune SA?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Unternehmen mit p / e ähnlich AC Immune SA
- Cosmo Lady (China) hat P / E von 4.18
- Immersion Corp hat P / E von 4.18
- Bank of China hat P / E von 4.18
- Nabaltec AG hat P / E von 4.18
- Brunner Investment Trust Plc hat P / E von 4.19
- JMP hat P / E von 4.19
- AC Immune SA hat P / E von 4.19
- Flaherty & Crumrine Total Return Fund Inc hat P / E von 4.20
- CWT International hat P / E von 4.20
- Cromwell Property Stapled Securities hat P / E von 4.20
- Syncona hat P / E von 4.20
- FANUC hat P / E von 4.20
- NorthWest Healthcare Properties Real Estate Investment Trust hat P / E von 4.20